drugset
drugset / Trial / NCT04914351

HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours

NCT04914351 ↗

Phase 1 Completed 17 enrolled Shanghai HyaMab Biotech Co.,Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase I, first-in-human trial to evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of HY-0102 administered intravenously (IV) once every two weeks in adult patients with locally advanced/metastatic malignant solid tumors.

Timeline

Start
2022-05-03
Primary completion
2023-11-27
Completion
2023-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HY-0102 Monoclonal antibody 0.03 mg/kg Intravenous
Subject HY-0102 Monoclonal antibody 0.3 mg/kg Intravenous
Subject HY-0102 Monoclonal antibody 1 mg/kg Intravenous
Subject HY-0102 Monoclonal antibody 2 mg/kg Intravenous
Subject HY-0102 Monoclonal antibody 4 mg/kg Intravenous
Subject HY-0102 Monoclonal antibody 10 mg/kg Intravenous

Indications

No indication recorded.